Introduction Esketamine-induced dissociation is a transient, pharmacologically mediated alteration in consciousness, often distinct from pathological dissociation. While not required for clinical improvement, these states may engage neural circuits implicated in therapeutic change. Objectives This study explores patients’ lived experiences of dissociation as potentially meaningful transitional...
Ketamine and esketamine ("es/ketamine") treatment protocols have been investigated in patients' samples with treatment-refractory anxiety disorders. We systematically reviewed publications in which es/ketamine was used to treat anxiety symptoms in the context of either Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) anxiety disorders or treatment-resistant...
Depression is a mental health disorder that requires accurate detection and effective treatment. Electroencephalography (EEG) based analysis has emerged as a promising approach for objective depression evaluation. This study leverages selected EEG features using hybrid feature selection approach to train an EoXGBoost model and evaluates its generalization on unlabeled posttest depression data....
European PsychiatryJune 1, 2026N. Aguayo-Verdugo, N. Ulloa-Chamblás, R. Zúñiga-Tapia et al.
Introduction University students, particularly in health-related fields, face rising levels of stress, anxiety, and depression, which negatively affect academic performance, social engagement, and overall well-being. Post-pandemic challenges, such as social isolation, uncertainty, and abrupt transitions to online learning, have exacerbated these issues. Mindfulness-based interventions (MBIs)...
European PsychiatryJune 1, 2026O. Płaza, Robert Madejek, M. M. Dutsch-Wicherek et al.
Introduction Treatment-resistant depression (TRD), which affects about 30% of patients with major depressive disorder, emerges when patients do not respond adequately to at least two antidepressant trials of proper dose and duration. The EMA approved esketamine nasal spray, the first registered psychedelic medication, in 2019 for TRD treatment. In July 2023, Poland launched B.147, the country’s...
Introduction Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce Objectives This study aimed to evaluate the long-term effectiveness and tolerability of...
Introduction Hopes related to esketamine have been raised by its approval for treatment-resistant major depression (TRD) in the sense that this antidepressant, with a novel mechanism of action, will be useful for patients with bipolar depression (BD), too. The need to find more evidence-based pharmacological approaches to both TRD and BD is acute due to the high rates of partial response or...
Introduction Adult attention-deficit/hyperactivity disorder (ADHD) frequently co-occurs with mood and anxiety disorders (Sandstrom et al. Acta Psychiatr Scand 2021;143 380–391), and when major depressive disorder (MDD) is present, it often follows a treatment-resistant course (Thapar et al. J Child Psychol Psychiatry 2023;64 4–15). Intranasal esketamine, a non-competitive NMDA-receptor...
Introduction Suicidality represents a major clinical and public health challenge, particularly among patients with treatment-resistant depression (TRD), who carry a disproportionately high risk of suicide. Traditional antidepressants often have delayed onset and limited efficacy in reducing suicidal ideation in this high-risk population, highlighting the need for rapid-acting interventions....
A two‐year extension of a trial of esketamine nasal spray in patients with treatment‐resistant depression has found no new safety concerns associated with long‐term use of the drug. The overall relapse rate across both the original trial and the extension was 6.9%.
Introduction Treatment-Resistant Depression (TRD) is a major clinical challenge, affecting about 30% of patients with major depressive disorder. It is associated with high morbidity and mortality, reflected in increased suicide risk, hospitalizations, and impaired quality of life. Electroconvulsive Therapy (ECT) remains the therapeutic gold standard, particularly in severe cases with psychotic...
Introduction Ketamine-assisted therapy shows rapid benefit in treatment-resistant depression, anxiety, and PTSD (Walsh et al. BJPsych Open 2022;8:e19). The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a unique 12-week program that combines 12 Community of Practice (group therapy) sessions and three ketamine medicine sessions (Tsang et al. Ther Adv Psychopharmacol...
Aims: Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist used for anaesthesia and analgesia, with increasing interest in its rapid antidepressant effects. This case evaluates the feasibility, tolerability and clinical response to subcutaneous ketamine in a medically frail older adult with psychotic depression, hypothesising that ketamine would rapidly improve engagement and...
Introduction Ketamine therapy for treatment-resistant depression has a well-established rapid antidepressant effect for acute symptom management. However, there is far less research on the efficacy of long-term maintenance therapy for relapse prevention. Objectives To examine the utility of long-term maintenance therapy with ketamine infusions delivered in a naturalistic treatment setting....
Journal of Computer ScienceJune 1, 2026Santiago Domingo Moquillaza Henríquez, Liliana Ruth Huamán Rondón, Nestor Marcial Alvarado Bravo et al.
Depression is a global mental health problem with various causes. Nowadays, with Artificial Intelligence, it can be predicted in order to take preventive measures, whether at a psychotherapeutic or pharmacological level. This research, based on a survey conducted, detects depression using logistic regression with a 91% fit to the ROC-AUC model, accuracy of 0.839188, precision 0.851354. In...
Introduction Treatment-resistant depression (TRD) represents a major challenge in psychiatry. Nearly one-third of patients with major depressive disorder fail to achieve remission despite adequate antidepressant therapy, and about 30% attempt suicide during their lifetime. Given this elevated risk, identifying treatments that rapidly reduce depressive symptoms and suicidality while improving...
Treatment-resistant depression (TRD), a persistent condition impacting up to 30% of patients with major depressive disorder, carries substantial personal and economic burden. There remains an unmet need for therapies that provide both rapid and durable improvements in TRD. Preliminary clinical trials indicate that GH001, a synthetic, inhalable formulation of mebufotenin, has the potential for...
Introduction TBI patients often suffer from severe, treatment-resistant depression and PTSD. Ketamine shows promise in non-TBI populations, but its efficacy in TBI patients needs exploration for efficacy and tolerability. Objectives Evaluate ketamine’s clinical effectiveness and safety (PHQ-9, GAD-7, PCL-5 scores) in post-TBI patients, comparing IM, intranasal, and oral routes. Methods Design:...
HEARTYJune 1, 2026Ita Apriliyani, Noor Yunida Triana
Depression is one of the psychological disorders experienced by many single mothers due to economic pressure, parenting responsibilities, and lack of social support. This condition has an impact on quality of life and parenting skills. Mindfulness is a mindfulness-based intervention approach that has been shown to be effective in reducing symptoms of depression through emotional regulation...
Older Black adults experience disproportionately high rates of chronic pain (CP) and depression, yet inequities in access, recognition, and culturally resonant treatment persist. Mindfulness-based cognitive therapy (MBCT) is an evidence-based group intervention for depression with emerging promise for CP. However, adaptations for older Black adults with comorbid CP-depression remain...